Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Den

Showing results (431-440 of 492) with videos related to

Pageof 50
Sort By:
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|October 6, 2016
The effect of losartan therapy on ventricular function in Marfan patients with haploinsufficient or dominant negative FBN1 mutationsA W den Hartog, R Franken, M P van den Berg, et al.
Cancer Immunology, Immunotherapy : CII|September 1, 1996
Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strainsM R Krul, E J Tijhaar, J A Kleijne, et al.
Emerging Infectious Diseases|December 25, 2002
Legionnaires' disease at a Dutch flower show: prognostic factors and impact of therapyKamilla D Lettinga, Annelies Verbon, Gerrit-Jan Weverling, et al.
International Journal of Cardiology|April 16, 2013
Circulating transforming growth factor-β as a prognostic biomarker in Marfan syndromeRomy Franken, Alexander W den Hartog, Vivian de Waard, et al.
European Journal of Nuclear Medicine|January 1, 1985
The elimination rate of 123I-heptadecanoic acid after intracoronary and intravenous administrationF C Visser, M J van Eenige, E E van der Wall, et al.
Clinical Colorectal Cancer|January 17, 2015
A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignanciesCorina N Oldenhuis, Walter J Loos, Brooke Esteves, et al.
Neuropathology and Applied Neurobiology|February 12, 2009
Spinocerebellar ataxia type 6 (SCA6): neurodegeneration goes beyond the known brain predilection sitesK Gierga, H J Schelhaas, E R Brunt, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 9, 2019
Renal phospholipidosis and impaired magnesium handling in high-fat-diet-fed miceSteef Kurstjens, Bart Smeets, Caro Overmars-Bos, et al.
Neuropathology and Applied Neurobiology|November 1, 2007
Spinocerebellar ataxia type 7 (SCA7): widespread brain damage in an adult-onset patient with progressive visual impairments in comparison with an adult-onset patient without visual impairmentsU Rüb, E R Brunt, K Seidel, et al.
Expert Review of Cardiovascular Therapy|August 2, 2022
P2Y<sub>12</sub>-inhibitor monotherapy after coronary stenting: are all P2Y<sub>12</sub>-inhibitors equal?Niels Mr van der Sangen, I Tarik Küçük, Jurriën M Ten Berg, et al.
Pageof 50

Showing results (431-440 of 492) with videos related to

Sort By:
Pageof 50
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|October 6, 2016
The effect of losartan therapy on ventricular function in Marfan patients with haploinsufficient or dominant negative FBN1 mutationsA W den Hartog, R Franken, M P van den Berg, et al.
Cancer Immunology, Immunotherapy : CII|September 1, 1996
Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strainsM R Krul, E J Tijhaar, J A Kleijne, et al.
Emerging Infectious Diseases|December 25, 2002
Legionnaires' disease at a Dutch flower show: prognostic factors and impact of therapyKamilla D Lettinga, Annelies Verbon, Gerrit-Jan Weverling, et al.
International Journal of Cardiology|April 16, 2013
Circulating transforming growth factor-β as a prognostic biomarker in Marfan syndromeRomy Franken, Alexander W den Hartog, Vivian de Waard, et al.
European Journal of Nuclear Medicine|January 1, 1985
The elimination rate of 123I-heptadecanoic acid after intracoronary and intravenous administrationF C Visser, M J van Eenige, E E van der Wall, et al.
Clinical Colorectal Cancer|January 17, 2015
A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignanciesCorina N Oldenhuis, Walter J Loos, Brooke Esteves, et al.
Neuropathology and Applied Neurobiology|February 12, 2009
Spinocerebellar ataxia type 6 (SCA6): neurodegeneration goes beyond the known brain predilection sitesK Gierga, H J Schelhaas, E R Brunt, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 9, 2019
Renal phospholipidosis and impaired magnesium handling in high-fat-diet-fed miceSteef Kurstjens, Bart Smeets, Caro Overmars-Bos, et al.
Neuropathology and Applied Neurobiology|November 1, 2007
Spinocerebellar ataxia type 7 (SCA7): widespread brain damage in an adult-onset patient with progressive visual impairments in comparison with an adult-onset patient without visual impairmentsU Rüb, E R Brunt, K Seidel, et al.
Expert Review of Cardiovascular Therapy|August 2, 2022
P2Y<sub>12</sub>-inhibitor monotherapy after coronary stenting: are all P2Y<sub>12</sub>-inhibitors equal?Niels Mr van der Sangen, I Tarik Küçük, Jurriën M Ten Berg, et al.
Pageof 50